Member Info for BuenaVista

I think it might be useful to concentrate on the fact that AVA6000, or ferry docks as we now need to call it, isn't red enough.

🤣 Watching two morons arguing.🤣 🤣 🤣

Just read checkricky's posting history and ignore.

https://www.lse.co.uk/profiles/checkricky/

Seriously, just ignore.

Just read Hemotruth's posting history and ignore.

https://www.lse.co.uk/profiles/hemotruth/

Seriously, just ignore.

Aldebaran is a keen trader, same as on the other boards where he posts and previously as Moneysponge until he disappeared on 13 December 2023 immediately after the hype that preceded Avacta's big data reveal. He thinks he's a glib persuader, either for or against a share depending on whether he's in or out until he commits with conviction, but his lack of education in basic spelling makes him look stupid. Read or filter, but don't pay too much attention to what he says. DYOR, as they say.

Also, never trust a poster who always has a 'Strong Buy' opinion. Their critical thinking and judgement is suspect and they're liable to lose themselves in flights of fancy.

Finally, developments (almost) always take longer than you think/expect/believe/hope and Hemogenyx is only at the beginning of the clinical development process so, unless you're happy with a quick win at a not very good price, be prepared to wait years for whatever true value there may be to come through.

Got to say I'm enjoying reading the cult postings here. Very amusing.

Well someone/people were selling in bulk this morning and there's no news and no reason for that sell-off other than some already very rich people receiving a whole cart load of 63p shares yesterday. There's a reason why they are very rich.

The scientific foundation was never "much shakier than many thought" once the pre|CISION dipeptide was shown to be exquisitely specific for the FAPα enzyme in vitro, in animals and then in humans.

Good summaries, especially Thompi's (but it was a £16m placing).

If you want to know where we are in detail, read the RNS:s from May this year (when there were severe funding concerns) onwards and watch the Spotlight series of background videos on the Avacta website as well as the explainer videos and interviews.

I think this is more aimed at rare genetic diseases and malignancies, so CRISPR gene editing and CAR-T therapies and suchlike, but may include rare cancers, although the UK has an equivalent of the US's ODD (called Orphan Medicinal Product Designation), as does the EU: https://www.google.com/search?q=what+is+the+UK+equivalent+of+the+US's+orphan+drug+designation

Anyway, this is what the boss of the MHRA said:

"A significant set of reforms that we're signalling to take place for next year and this is all about giving hope to those many patients, as you say two and a half million patients in this country, who have one or more rare diseases and for whom in the past they've had relatively few treatment options. So the reforms we're signalling today, to come into force next year, will allow us to speed many of these new medicines that have been developed with the science we have today of personalised medicine and our ability to manipulate the cells and the genes of the individual to treat their rare diseases."

It's not a 'narrow therapeutic index', it's either a narrow therapeutic window or a low therapeutic index, you smug moron.

I'm not predicting anything. I'm just stating a fact. You should try it. It might improve your credibility, although you've probably gone too far down Twat Street for anyone to ever take you seriously.

Wtf is a "narrow therapeutic index"?

There hasn't been a head to head with standard doxorubicin in any indication you moron.

I don't know whether you are obtuse or just really, really thick.

There hasn't been a head to head with standard doxorubicin you moron.

Three things are needed for success: science that works; results that are statistically significant; and funds to get to the company's desired endpoint.

If the desired endpoint is short-term in the development-to-market process, a takeout will be at a low price as the risk will be taken on by the buyer.

If the desired endpoint is longer-term, the need for additional funding will dilute the equity but, on statistically reliable results, any takeout will be at a much higher price.

Essentially, it's really that simple. So what is Vlad's desired endoint? It's his intellectual property and his company - he is the brains of the organisation.

30 Sep 2025: https://www.lse.co.uk/rns/AVCT/interim-half-year-results-2025-xtgyescwh7u4pla.html

The RNS was issued on Monday 27 October at 07:00

https://www.londonstockexchange.com/news-article/AVCT/avacta-presents-preclinical-data-at-aacr-nci-eortc/17296010

The same announcement was released as a Globe Newswire press release (what passes for an RNS in the US), which was picked up and reproduced by the Financial Times, etc.

https://www.globenewswire.com/news-release/2025/10/25/3174179/0/en/Avacta-presents-first-preclinical-data-from-dual-payload-pre-CISION-medicines-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets.html

https://markets.ft.com/data/announce/detail?dockey=1330-1001135036en-0MVP9R4RGF54UDQ95KPC6A078M

https://uk.finance.yahoo.com/news/avacta-presents-first-preclinical-data-171400537.html

- - - - -

I'm 100% sure they will be optimising the capping group and linker of the dual-payload AVA6207. Only Compound A, Compound B, etc. were presented on the poster but, if anything like with AVA6103, they will be deciding on the compound to take forward at some later time, maybe Compound X.

No, it's one of the national priorities specified in this CNPV program. CC said manufacture in the US applied to tariffs on marketted products only. AVA6000 is a research product, but large scale production for the marketted product will no doubt be done in the US.

Very much, I'd say. This week's update of the NCT04969835 record for AVA6000 removed the 'NO' answer from the Manufactured in the US prompt. We know that AVA6000 had previously been manufactured in Switzerland so I'd guess it is now being manufactured in the US, or will be when old stock has been used up or the Swiss contract expires. AVA6103 will surely be manufactured in the US as CC is Americanizing - see, I'm learning - everything.

It's clear that ArchBishopHolmes is a complete idiot ... "during Wednesday Avacta presentation their CEO said it was based on a TWO WEEK OLD discovery lol"... Er, no, the CEO said the patent was FILED two weeks ago, so patent life will be until 2045. And the rest of your post is just pure ignorant drivel.

I pity anyone who relies on that moron for facts about anything, especially Hemogenyx.

So... Bish, bash, bosh, in the green bin you go.